Invivyd (IVVD) Return on Sales (2024 - 2025)
Invivyd (IVVD) posted Return on Sales of 0.01% for Q4 2025, up 21.16% on a QoQ basis from 0.01% in Q3 2025, and up 1.0% year-over-year from 0.01% in Q4 2024.
Invivyd (IVVD) Return on Sales (2024 - 2025) Analysis & Trends
Invivyd's Return on Sales history runs 2 years deep, the most recent figure standing at 0.01% for Q4 2025.
- Quarterly Return on Sales rose 1.0% year-over-year to 0.01% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.01% (up 7.0% YoY) and the FY2025 annual result came in at 0.06%, up 11.0% from the prior year.
- Return on Sales was 0.01% for Q4 2025 at Invivyd, up from 0.01% in the prior quarter.
- Across five years, Return on Sales topped out at 0.01% in Q4 2025 and bottomed at 0.22% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.00% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn | -0.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.02% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.07% |
| Jun 30, 2024 | -0.22% |